In summary, current evidence supports a largely oncogenic function of ADAR1-driven A-to-I editing in cancer, whereas ADAR2 might possesses tumor suppressive or pro-tumorigenic function in a cancer type-specific and context-dependent manner. This evidence concerns the gene ADAR and neoplasm.